Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Passage BIO, Inc.

Ticker
PASG
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include Passage BIO's stockholders approving merger proposals and a reverse stock split in November 2026, the announcement of an all-stock merger agreement with Remix Therapeutics in June 2026, and analyst coverage initiating buy and outperform recommendations.

Recent developments:
  • Passage BIO stockholders approved merger proposals, a reverse stock split from 1-for-2 to 1-for-10, and a name change in November 2026 [N1].
  • The company entered into an all-stock merger agreement with Remix Therapeutics in June 2026, with the merger anticipated to close in Q4 2026 subject to customary conditions [N3][S2].
  • Analysts including Oppenheimer and Chardan Capital initiated coverage with outperform and buy recommendations respectively [N4][N5].
  • Passage BIO reported a decrease in Q3 losses in November 2025, reflecting some operational progress [N6].
  • The company reported positive interim clinical data for its PBFT02 gene therapy candidate in frontotemporal dementia patients in prior periods [N6].
Overview

Passage BIO, Inc. operates in the genetic medicines sector, focusing on developing gene therapies for rare diseases. The company has ongoing research and development programs, including clinical trials for its PBFT02 candidate targeting frontotemporal dementia. Passage BIO's business model centers on advancing its pipeline through clinical development and strategic collaborations. The company has recently entered into a merger agreement with Remix Therapeutics, which involves an all-stock transaction and contingent value rights related to legacy sublicenses. Passage BIO's financial condition reflects recurring operating losses and limited cash resources, raising concerns about its ability to continue as a going concern without additional financing or strategic transactions. The merger agreement imposes operational restrictions pending closing and may affect business flexibility.

Executive summary

Passage BIO, Inc. is a US-based genetic medicines company with detailed disclosures in recent SEC filings including a 10-K for fiscal year ended December 31, 2025, and a 10-Q for the quarter ended September 30, 2026. The company reported a net loss of $4.72 million and negative EPS of $1.47 for Q3 2026, with cash and equivalents of approximately $20.16 million as of September 30, 2026. Passage BIO entered into an all-stock merger agreement with Remix Therapeutics in June 2026, subject to customary closing conditions and anticipated to close in Q4 2026. Stockholders approved merger proposals and a reverse stock split in November 2026. The merger exchange ratio is formula-based and not dependent on market price, with current stockholders expected to own about 6% of the combined company post-merger. The company faces substantial doubt about its ability to continue as a going concern within one year due to recurring losses and cash usage. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for PASG

Bull case model:

The merger with Remix Therapeutics could create a combined entity with enhanced capabilities and a broader pipeline in genetic medicines. Positive interim clinical data for PBFT02 and other pipeline candidates support the company's scientific progress. Analyst coverage with buy and outperform recommendations reflects market interest in the company's potential. Successful execution of the merger and pipeline advancement could strengthen the company's strategic position.

Bear case model:

Substantial doubt exists about Passage BIO's ability to continue as a going concern due to recurring losses and limited cash resources. The merger agreement restricts business operations and may delay or prevent alternative strategic transactions. There is no assurance that contingent value rights will yield payments, and stockholder dilution is significant post-merger. Clinical and regulatory risks inherent in gene therapy development may impact future prospects.

Moat:

Passage BIO's moat is primarily based on its proprietary gene therapy technology platform and its focus on rare genetic diseases with high unmet medical need. The company's clinical-stage pipeline and collaborations provide potential competitive advantages in specialized therapeutic areas. However, the biotechnology sector is highly competitive and subject to regulatory, clinical, and financial risks that may impact the company's ability to maintain its position.

Risks overview
Risks summary
The most significant risks include the uncertainty of merger completion, substantial doubt about the company's ability to continue as a going concern, and operational restrictions that may limit business flexibility pending the merger.
Risks details:

• Merger Completion Risk: The merger with Remix Therapeutics is subject to customary closing conditions that may not be satisfied or waived, potentially preventing completion and adversely affecting the company.
• Going Concern Uncertainty: Recurring operating losses and cash usage raise substantial doubt about the company's ability to continue as a going concern within one year after the September 30, 2026 financial statement date.
• Operational Restrictions Pending Merger: The merger agreement restricts the company's ability to pursue alternative transactions and requires operating in the ordinary course, which may limit business flexibility and opportunities.
• Stockholder Dilution and Reduced Influence: Post-merger, existing stockholders are expected to own approximately 6% of the combined company, reducing their ownership and voting influence.
• Contingent Value Rights Uncertainty: Payments under the contingent value rights related to legacy sublicenses depend on future payments from sublicensees, with no assurance of realization.

FINAL FORECAST FOR PASG

Final take one line
Passage BIO exhibits very high visibility with detailed SEC disclosures and recent news on its merger with Remix Therapeutics, facing execution and financial risks amid ongoing clinical development.
Final take 12 to 24 month view

Business trends: Passage BIO is advancing its gene therapy pipeline and pursuing a strategic merger with Remix Therapeutics to combine capabilities.
Execution milestones: Completion of the merger anticipated in Q4 2026, stockholder approvals secured, and ongoing clinical data releases.
Key risks: Merger completion uncertainty, going concern doubts due to recurring losses, operational restrictions pending merger, stockholder dilution, and contingent value rights payment uncertainty.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Passage BIO, Inc. is a US-based company listed on Nasdaq under ticker PASG [S1].
  • The company is engaged in genetic medicines, with research and development activities disclosed in SEC filings [S1].
  • As of September 30, 2026, Passage BIO had cash and cash equivalents of approximately $20.16 million and current assets of about $20.79 million, with current liabilities of approximately $20.74 million, resulting in a current ratio of 1.0 and a cash ratio of 0.97 [S2].
  • The company reported a net loss of $4.72 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$1.47 per share for the same period [S2].
  • Passage BIO entered into an all-stock merger agreement with Remix Therapeutics in June 2026, with the merger intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code [S2].
  • The merger agreement includes customary closing conditions and is anticipated to close in the fourth quarter of 2026, subject to satisfaction or waiver of conditions [S2].
  • The merger exchange ratio is fixed by formula based on agreed equity values and net cash at closing, not on market price, with current stockholders expected to own approximately 6% of the combined company post-merger [S2].
  • The merger involves issuance of contingent value rights (CVRs) to stockholders representing rights to potential future payments from sublicenses, with no assurance of payments being received [S2].
  • The merger agreement restricts Passage BIO from pursuing alternative transactions and requires operating in the ordinary course pending consummation, which may limit business flexibility [S2].
  • There is substantial doubt about Passage BIO's ability to continue as a going concern within one year after the September 30, 2026 financial statement date due to recurring losses and cash usage [S2].
  • Passage BIO stockholders approved merger proposals, a reverse stock split from 1-for-2 to 1-for-10, and a name change in November 2026 [N1].
  • The company has received buy and outperform recommendations from analysts such as Chardan Capital and Oppenheimer [N4][N5].
  • Recent news includes the merger agreement announcement with Remix Therapeutics in June 2026 and subsequent stockholder approvals [N3][N1].
  • The company has reported positive interim clinical data for its PBFT02 gene therapy candidate in frontotemporal dementia patients in prior periods [N6].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-03 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-11-06 | www.nasdaq.com | Passage Bio, Inc. Stockholders Approve Merger Proposals, Reverse Stock Split of 1-for-2 to 1-for-10, and Name Change | https://www.nasdaq.com/articles/passage-bio-inc-stockholders-approve-merger-proposals-reverse-stock-split-1-2-1-10-and
  • N2 | 2026-06-26 | www.nasdaq.com | Weekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired | https://www.nasdaq.com/articles/weekly-buzz-ions-mrk-get-fda-approvals-achv-gets-crl-adct-cuts-jobs-tech-acquired
  • N3 | 2026-06-25 | www.nasdaq.com | Passage Bio And Remix Therapeutics Enter All-Stock Merger Agreement; Stock Down | https://www.nasdaq.com/articles/passage-bio-and-remix-therapeutics-enter-all-stock-merger-agreement-stock-down
  • N4 | 2026-03-31 | www.nasdaq.com | Oppenheimer Initiates Coverage of Passage Bio (PASG) with Outperform Recommendation | https://www.nasdaq.com/articles/oppenheimer-initiates-coverage-passage-bio-pasg-outperform-recommendation
  • N5 | 2025-11-12 | www.nasdaq.com | Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation | https://www.nasdaq.com/articles/chardan-capital-maintains-passage-bio-pasg-buy-recommendation
  • N6 | 2025-11-11 | www.nasdaq.com | PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates | https://www.nasdaq.com/articles/passage-bio-inc-q3-loss-decreases-beats-estimates
  • N7 | 2025-09-01 | www.nasdaq.com | Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet | https://www.nasdaq.com/articles/wall-street-analysts-think-passage-bio-pasg-could-surge-731-read-placing-bet
  • N8 | 2025-08-15 | www.nasdaq.com | Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade | https://www.nasdaq.com/articles/wall-street-analysts-believe-passage-bio-pasg-could-rally-141515-heres-how-trade
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine